Arbutus Biopharma Corp - 10-Q Filing
Arbutus Biopharma reports Q3 2026 results including collaboration revenue and ongoing restructuring costs.
Tickers: $ABUS
Read the full article at SEC EDGAR
Part of the story ArriVent BioPharma, Inc. - 10-Q Filing (3 articles)